Sarepta Therapeutics Shares Down 3% Following FDA’s Clinical Hold Announcement
<p><a href='https://financialmodelingprep.com/financial-summary/SRPT'>Sarepta Therapeutics, Inc. (NASDAQ: SRPT)</a> shares were trading nearly 3% lower pre-market following the announcement that the U.S. Food and Drug Administration (FDA) placed a clinical hold on the company’s SRP-5051 following continued observations of low magnesium levels, a side effect previously observed with the drug, including an SAE.</p>
<p>Analysts at RBC Capital provided their views on the company following the announcement, stating they believe this side effect should be manageable with more proactive monitoring/intervention and the program should be able to get back on track.</p>
<p>While noting that the drug is important for the life cycle/floor, the analysts said that it is not the critical value driver, and they expect the company to manage through this issue regardless.</p>

NASDAQ:, SRPT